LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).
Phase 1/2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed / Refractory Osteosarcoma
Conditions
Relapsed / Refractory Osteosarcoma
Trial Timeline
Feb 1, 2026 → May 1, 2032
NCT ID
NCT07357519About LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).
LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). is a phase 1/2 stage product being developed by Lantheus Holdings for Relapsed / Refractory Osteosarcoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07357519. Target conditions include Relapsed / Refractory Osteosarcoma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed / Refractory Osteosarcoma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
9
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07357519 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Relapsed / Refractory Osteosarcoma